keine Finanzberatung

VTRS · Viatris

Global generics & off-patent drugs (Mylan + Pfizer's Upjohn)

Risiko 6/10 · MODERATE-HIGH RISK · declining generics · $16.88 ▼ 0.35%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $16.88
  • Market cap $19.4B
  • P/E (ttm) n/a
  • Div yield 2.84%
  • 52-wk range $9.43 – $18.39
  • Index rank #391 / —

Wichtigste Risiken

  • Base-business erosion outpaces new launches (Shareholders) — HIGH
  • Debt load sits against a shrinking earnings base (Bondholders) — MED
  • Pipeline fails to offset generic price decay (Shareholders) — MED
  • Manufacturing-quality problems at key plants resurface (Customers) — MED

Fazit

A cash-return cigar butt — it works only if the decline is slower than the price already implies.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.